 |
|
Neuroprotective and Anti–Human Immunodeficiency Virus Activity of Minocycline
M. Christine Zink, DVM, PhD;
Jennifer Uhrlaub, BS;
Jesse DeWitt, BS;
Tauni Voelker, BS;
Brandon Bullock, MS;
Joseph Mankowski, DVM, PhD;
Patrick Tarwater, PhD;
Janice Clements, PhD;
Sheila Barber, PhD
JAMA. 2005;293:2003-2011.
Context The prevalence of human immunodeficiency virus (HIV) central nervous system (CNS) disease has not decreased despite highly active antiretroviral therapy. Current antiretroviral drugs are expensive, have significant adverse effects including neurotoxicity, and few cross the blood-brain barrier.
Objective To examine the ability of minocycline, an antibiotic with potent anti-inflammatory and neuroprotective properties, to protect against encephalitis and neurodegeneration using a rapid, high viral load simian immunodeficiency virus (SIV) model of HIV-associated CNS disease that constitutes a rigorous in vivo test for potential therapeutics.
Design and Subjects Five SIV-infected pigtailed macaques were treated with 4 mg/kg per day of minocycline beginning at early asymptomatic infection (21 days after inoculation). Another 6 macaques were inoculated with SIV but remained untreated. Blood and cerebrospinal fluid (CSF) samples were taken on days 7, 10, 14, 21, 28, 35, 43, 56, 70, 77, and 84, and all macaques were humanely killed at 84 days after inoculation, a time that corresponds to late-stage infection in HIV-infected individuals.
Main Outcome Measures Blood and CSF samples were tested for viral load by real-time reverse transcription–polymerase chain reaction and levels of monocyte chemoattractant protein 1 were quantitated by enzyme-linked immunosorbent assay. The presence and severity of encephalitis was determined by microscopic examination of tissues. Central nervous system inflammation was further assessed by measuring infiltration and activation of macrophages, activation of p38 mitogen-activated protein kinase and expression of amyloid precursor protein by quantitative immunohistochemistry.
Results Minocycline-treated macaques had less severe encephalitis (P = .02), reduced CNS expression of neuroinflammatory markers (major histocompatibility complex class II, P = .03; macrophage marker CD68 , P = .07; T-cell intracytoplasmic antigen 1, P = .03; CSF monocyte chemoattractant protein 1, P = .001), reduced activation of p38 mitogen-activated protein kinase (P<.001), less axonal degeneration ( -amyloid precursor protein, P = .03), and lower CNS virus replication (viral RNA, P = .04; viral antigen, P = .04). In in vitro analysis, minocycline suppression of HIV and SIV replication in cultured primary macrophages did not correlate with suppression of activation of p38-mitogen-activated protein kinase pathways, whereas suppression in primary lymphocytes correlated with suppression of p38 activation.
Conclusions In this experimental SIV model of HIV CNS disease, minocycline reduced the severity of encephalitis, suppressed viral load in the brain, and decreased the expression of CNS inflammatory markers. In vitro, minocycline inhibited SIV and HIV replication. These findings suggest that minocycline, a safe, inexpensive, and readily available antibiotic should be investigated as an anti-HIV therapeutic.
Author Affiliations: Department of Comparative Medicine, Johns Hopkins University School of Medicine, Baltimore, Md (Drs Zink, Mankowski, Clements, and Barber; Mss Uhrlaub, and Voelker; and Messrs DeWitt and Bullock); Department of Biostatistics and Epidemiology, University of Texas Health Science Center at Houston, School of Public Health, El Paso Regional Campus, El Paso (Dr Tarwater).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Effects of Minocycline and Valproic Acid Coadministration on Atazanavir Plasma Concentrations in Human Immunodeficiency Virus-Infected Adults Receiving Atazanavir-Ritonavir
DiCenzo et al.
Antimicrob. Agents Chemother. 2008;52:3035-3039.
ABSTRACT
| FULL TEXT
Minocycline inhibits West Nile virus replication and apoptosis in human neuronal cells
Michaelis et al.
J Antimicrob Chemother 2007;60:981-986.
ABSTRACT
| FULL TEXT
Identification of potential HIV-1 targets of minocycline
Jenwitheesuk and Samudrala
Bioinformatics 2007;23:2797-2799.
ABSTRACT
| FULL TEXT
Copolymer-1 Induces Adaptive Immune Anti-inflammatory Glial and Neuroprotective Responses in a Murine Model of HIV-1 Encephalitis
Gorantla et al.
J. Immunol. 2007;179:4345-4356.
ABSTRACT
| FULL TEXT
Minocycline Modulates Neuroinflammation Independently of Its Antimicrobial Activity in Staphylococcus aureus-Induced Brain Abscess
Kielian et al.
Am. J. Pathol. 2007;171:1199-1214.
ABSTRACT
| FULL TEXT
Therapy with Minocycline Aggravates Experimental Rabies in Mice
Jackson et al.
J. Virol. 2007;81:6248-6253.
ABSTRACT
| FULL TEXT
Novel Pathway for Induction of Latent Virus from Resting CD4+ T Cells in the Simian Immunodeficiency Virus/Macaque Model of Human Immunodeficiency Virus Type 1 Latency
Shen et al.
J. Virol. 2007;81:1660-1670.
ABSTRACT
| FULL TEXT
Randomized Phase II Trial of Matrix Metalloproteinase Inhibitor COL-3 in AIDS-Related Kaposi's Sarcoma: An AIDS Malignancy Consortium Study
Dezube et al.
JCO 2006;24:1389-1394.
ABSTRACT
| FULL TEXT
Modulating CCR2 and CCL2 at the blood-brain barrier: relevance for multiple sclerosis pathogenesis
Mahad et al.
Brain 2006;129:212-223.
ABSTRACT
| FULL TEXT
Acne, Antibiotics, and Upper Respiratory Tract Infections
Chan and Shaw
Arch Dermatol 2005;141:1157-1158.
FULL TEXT
Minocycline Appears Protective Against HIV CNS Disease
JWatch Infect. Diseases 2005;2005:3-3.
FULL TEXT
An Old Antibiotic May Offer New Hope in HIV-Associated Encephalitis
AIDS Clin Care 2005;2005:8-8.
FULL TEXT
|
